| Ytd | 0.71% | |
| 1y | 3.92% |
| Open | 49.60 | Prev Close | 49.90 | Low | 49.57 | High | 49.77 | Mkt Cap | 15.23B |
| Vol | 14.33K | Avg Vol | 495.42K | EPS | 2.27 | P/E | 21.85 | Forward P/E | 19.10 |
| Beta | N/A | Short Ratio | 8.79 | Inst. Own | 57.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-31 | Earning | 11-06 | 50-d Avg | 52.62 | 200-d Avg | 51.19 | 1yr Est | 62.50 |
EMA News
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Austra
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the
BATON ROUGE, La., Aug. 12, 2026 /PRNewswire/ -- Bernhard Capital Partners ("Bernhard"), an infrastru
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced the transaction to
Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr
Emera TSE: EMA reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as t
Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e
Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 second qua
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next g
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FD
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced it has received fi
Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 202
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden
HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/N
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release it
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (E
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults w
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 C
Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr
Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus est
Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus est
Wall Street analysts changed outlook on top names. Check analyst ratings page for full view. See wha
Top Wall Street analysts changed outlooks on top stocks. Check out our analyst ratings page for upgr
Barclays analyst Michael Lonegan initiates coverage on Emera (NYSE:EMA) with a Equal-Weight ratin
Emera (NYSE:EMA) reported quarterly earnings of $0.39 per share which missed the analyst consensus e
Emera Incorporated ("Emera" or the "Company") (NYSE:EMA) announced today that it has
